Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia

• Published in: European psychiatry Vol. 26; no. 5; pp. 297 - 301
• Main Authors: Heres, S, Reichhart, T, Hamann, J, Mendel, R, Leucht, S, Kissling, W
• Format: Journal Article
• Language: English
• Published: Paris Elsevier SAS 01.07.2011; Elsevier
• Subjects: Adult; Adult and adolescent clinical studies; Antipsychotic; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - therapeutic use; Attitude; Attitude of Health Personnel; Biological and medical sciences; Depot; Female; First episode; Health Care Surveys; Humans; Internal Medicine; Male; Medical sciences; Middle Aged; Neuropharmacology; Pharmacology. Drug treatments; Psychiatry; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Psychoses; Schizophrenia; Schizophrenia - drug therapy; first episode patients; FGA; Attitude; second generation antipsychotics; Schizophrenia; SGA; FEP; SD; First episode; Psychopharmacology; Antipsychotic; Depot; first generation antipsychotics; standard deviation; Human; Health staff; Neuroleptic; Psychotropic; Pharmacotherapy; Psychiatrist; Psychosis; Treatment
• ISSN: 0924-9338; 1778-3585
• DOI: 10.1016/j.eurpsy.2009.12.020

Abstract Objective Despite good clinical evidence, depot antipsychotics are only seldom prescribed to patients with first episode schizophrenia. The present study aims at investigating psychiatrists’ reasons for this reservation. Method We surveyed 198 psychiatrists on their attitude toward offering depot treatment to first episode patients (FEP). Participants scored the extent of influence of individual factors on their decision on a seven-point-scale, additional data on their prescription practice and estimation of the relapse risk of FEP were collected. Results Psychiatrists reported that only three out of 12 factors were of influence. These were the limited availability of different second generation antipsychotic depot drugs, the frequent rejection of the depot offer by the patients and the patients’ skepticism based on the lack in experience of a relapse. Conclusions There is actually little specific reason for not prescribing depot to FEP according to the current survey. For those factors being reported to be of influence, psychoeducation, including profound information on depot treatment, the development of additional SGA depot drugs and the standard offer of depot treatment to all FEP in a shared-decision-making may be considered.